FI964311L - Bifunktionaalinen proteiini, valmistus ja käyttö - Google Patents
Bifunktionaalinen proteiini, valmistus ja käyttö Download PDFInfo
- Publication number
- FI964311L FI964311L FI964311A FI964311A FI964311L FI 964311 L FI964311 L FI 964311L FI 964311 A FI964311 A FI 964311A FI 964311 A FI964311 A FI 964311A FI 964311 L FI964311 L FI 964311L
- Authority
- FI
- Finland
- Prior art keywords
- preparation
- bifunctional protein
- bifunctional
- protein
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94810244 | 1994-05-02 | ||
| EP94810244 | 1994-05-02 | ||
| EP9501494 | 1995-04-20 | ||
| PCT/EP1995/001494 WO1995030014A1 (en) | 1994-05-02 | 1995-04-20 | Bifunctional protein, preparation and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI964311L true FI964311L (fi) | 1996-10-25 |
| FI964311A0 FI964311A0 (fi) | 1996-10-25 |
| FI119191B FI119191B (fi) | 2008-08-29 |
Family
ID=8218248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI964311A FI119191B (fi) | 1994-05-02 | 1996-10-25 | Bifunktionaalinen proteiini, valmistus ja käyttö |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6984382B1 (fi) |
| EP (1) | EP0758394B1 (fi) |
| JP (1) | JP3742103B2 (fi) |
| KR (1) | KR100373813B1 (fi) |
| AT (1) | ATE228166T1 (fi) |
| AU (1) | AU694222B2 (fi) |
| CA (1) | CA2188422C (fi) |
| DE (1) | DE69528894T2 (fi) |
| DK (1) | DK0758394T3 (fi) |
| ES (1) | ES2185705T3 (fi) |
| FI (1) | FI119191B (fi) |
| IL (1) | IL113530A0 (fi) |
| NO (1) | NO316923B1 (fi) |
| NZ (1) | NZ285395A (fi) |
| PT (1) | PT758394E (fi) |
| TW (1) | TW428026B (fi) |
| WO (1) | WO1995030014A1 (fi) |
| ZA (1) | ZA953440B (fi) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995030014A1 (en) | 1994-05-02 | 1995-11-09 | Ciba-Geigy Ag | Bifunctional protein, preparation and use |
| EP0870040A2 (en) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Gene delivery vehicle-targeting ligands |
| WO1998012227A1 (en) * | 1996-09-19 | 1998-03-26 | Diagnocure Inc. | Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| DE10121113A1 (de) * | 2001-04-28 | 2002-10-31 | Gabriele Pecher | Genmodifizierte YT Zelllinie und ihre Verwendung |
| DK3406631T3 (da) | 2004-07-10 | 2022-08-29 | The Institute For Cancer Res | Genetisk modificerede humane naturlige dræbercellelinjer |
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
| RU2487888C2 (ru) * | 2006-06-12 | 2013-07-20 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи | Одноцепочечные мультивалентные связывающие белки с эффекторной функцией |
| US20100105136A1 (en) * | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US12492376B2 (en) | 2009-10-29 | 2025-12-09 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| WO2013169691A1 (en) | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| WO2014100615A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| KR102685501B1 (ko) | 2013-02-20 | 2024-07-17 | 노파르티스 아게 | 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료 |
| EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| EP3623380B1 (en) | 2013-03-15 | 2025-10-22 | Novartis AG | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| JP6779785B2 (ja) | 2013-12-19 | 2020-11-04 | ノバルティス アーゲー | ヒトメソテリンキメラ抗原受容体およびその使用 |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| TWI718992B (zh) | 2014-07-21 | 2021-02-21 | 瑞士商諾華公司 | 使用cll-1嵌合抗原受體治療癌症 |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| TW202140557A (zh) | 2014-08-19 | 2021-11-01 | 瑞士商諾華公司 | 使用cd123嵌合抗原受體治療癌症 |
| MX2017003645A (es) | 2014-09-17 | 2017-05-30 | Novartis Ag | Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva. |
| CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| IL253149B2 (en) | 2014-12-29 | 2023-11-01 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| JP7114457B2 (ja) | 2015-04-17 | 2022-08-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法 |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| MX2018006767A (es) | 2015-12-04 | 2019-03-14 | Novartis Ag | Composiciones y metodos para oncologia inmunologica. |
| US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| MY200337A (en) | 2016-10-07 | 2023-12-20 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| BR112019018124A2 (pt) | 2017-03-22 | 2020-04-07 | Intellia Therapeutics Inc | composições e métodos para imunooncologia |
| JP7585034B2 (ja) | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| US12539308B2 (en) | 2018-01-08 | 2026-02-03 | The Trustees Of The University Of Pennsylvania | Immune-enhancing RNAs for combination with chimeric antigen receptor therapy |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
| CN110627895B (zh) * | 2018-06-25 | 2021-03-23 | 北京大学 | 肺癌特异性tcr及其分析技术和应用 |
| CN112912105B (zh) | 2018-08-31 | 2024-07-16 | 因维克蒂斯股份有限公司 | 针对多种hla-g同种型的嵌合抗原受体 |
| US20220221455A1 (en) * | 2019-04-18 | 2022-07-14 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
| CA3163104A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| KR20220104217A (ko) | 2019-11-26 | 2022-07-26 | 노파르티스 아게 | Cd19 및 cd22 키메라 항원 수용체 및 이의 용도 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0260880A3 (en) | 1986-09-11 | 1990-03-07 | Dana-Farber Cancer Institute, Inc. | Turning on of cytotoxicity |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| FI105320B (fi) | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
| DE69128893T2 (de) | 1990-10-31 | 1998-09-10 | Brigham & Womens Hospital | Genetische veränderung von endothelzellen |
| KR100246529B1 (ko) * | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
| AU662311B2 (en) * | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| FR2672901B1 (fr) | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
| AU1453792A (en) | 1991-02-27 | 1992-10-06 | Regents Of The University Of California, The | Targeting complex mediated immunogenicity |
| IL101147A (en) | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
| WO1993019163A1 (en) * | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
| CA2118026A1 (en) | 1992-04-14 | 1993-10-28 | Guy T. Layton | Induction of ctl responses |
| WO1995030014A1 (en) | 1994-05-02 | 1995-11-09 | Ciba-Geigy Ag | Bifunctional protein, preparation and use |
-
1995
- 1995-04-20 WO PCT/EP1995/001494 patent/WO1995030014A1/en not_active Ceased
- 1995-04-20 KR KR1019960706165A patent/KR100373813B1/ko not_active Expired - Fee Related
- 1995-04-20 NZ NZ285395A patent/NZ285395A/xx not_active IP Right Cessation
- 1995-04-20 AT AT95918576T patent/ATE228166T1/de active
- 1995-04-20 EP EP95918576A patent/EP0758394B1/en not_active Expired - Lifetime
- 1995-04-20 JP JP52796595A patent/JP3742103B2/ja not_active Expired - Fee Related
- 1995-04-20 PT PT95918576T patent/PT758394E/pt unknown
- 1995-04-20 ES ES95918576T patent/ES2185705T3/es not_active Expired - Lifetime
- 1995-04-20 DK DK95918576T patent/DK0758394T3/da active
- 1995-04-20 AU AU24469/95A patent/AU694222B2/en not_active Ceased
- 1995-04-20 CA CA2188422A patent/CA2188422C/en not_active Expired - Lifetime
- 1995-04-20 DE DE69528894T patent/DE69528894T2/de not_active Expired - Lifetime
- 1995-04-24 TW TW084103999A patent/TW428026B/zh active
- 1995-04-28 ZA ZA953440A patent/ZA953440B/xx unknown
- 1995-04-28 IL IL11353095A patent/IL113530A0/xx not_active IP Right Cessation
-
1996
- 1996-10-25 FI FI964311A patent/FI119191B/fi not_active IP Right Cessation
- 1996-11-01 NO NO19964641A patent/NO316923B1/no not_active IP Right Cessation
-
2000
- 2000-06-19 US US09/596,774 patent/US6984382B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FI119191B (fi) | 2008-08-29 |
| NO964641D0 (no) | 1996-11-01 |
| CA2188422A1 (en) | 1995-11-09 |
| DE69528894T2 (de) | 2003-03-27 |
| PT758394E (pt) | 2003-04-30 |
| FI964311A0 (fi) | 1996-10-25 |
| JPH09512176A (ja) | 1997-12-09 |
| ZA953440B (en) | 1995-11-02 |
| EP0758394A1 (en) | 1997-02-19 |
| AU694222B2 (en) | 1998-07-16 |
| DK0758394T3 (da) | 2003-03-03 |
| TW428026B (en) | 2001-04-01 |
| NZ285395A (en) | 1998-10-28 |
| WO1995030014A1 (en) | 1995-11-09 |
| ES2185705T3 (es) | 2003-05-01 |
| DE69528894D1 (de) | 2003-01-02 |
| EP0758394B1 (en) | 2002-11-20 |
| US6984382B1 (en) | 2006-01-10 |
| IL113530A0 (en) | 1995-07-31 |
| AU2446995A (en) | 1995-11-29 |
| CA2188422C (en) | 2011-03-15 |
| NO316923B1 (no) | 2004-06-28 |
| JP3742103B2 (ja) | 2006-02-01 |
| NO964641L (no) | 1996-11-01 |
| KR100373813B1 (ko) | 2003-10-08 |
| ATE228166T1 (de) | 2002-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI964311L (fi) | Bifunktionaalinen proteiini, valmistus ja käyttö | |
| FI955235A7 (fi) | Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö | |
| NL300295I2 (nl) | 3,3-diarylpropylaminen, de toepassing en bereidinghiervan | |
| FI961457L (fi) | Uusi kompleksiyhdiste, sen valmistus ja käyttö | |
| FI940904L (fi) | Oksatsolidiinidionijohdannaiset, niiden valmistus ja käyttö | |
| FI951468A7 (fi) | Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö | |
| FI951817A7 (fi) | Orgonaluminoksituote, sen valmistus ja käyttö | |
| FI954763A7 (fi) | Oksiinijohdannaiset, niiden valmistus ja niiden terapeuttinen käyttö | |
| FI972245A0 (fi) | Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät | |
| FI902629A7 (fi) | Aryylioksifenyylipropyyliamiineja, niiden valmistus ja käyttö | |
| FI900461A7 (fi) | Imidatsopyridatsiinit, niiden valmistus ja käyttö | |
| FI970997A7 (fi) | Bentsosykloalkeeniyhdisteet, niiden valmistus ja käyttö | |
| FI964267A7 (fi) | Porfosyaniini ja CNC-laajennetut porfyriinit | |
| FI940425A7 (fi) | Modifioidut oligodeoksiribonukleotidit, niiden valmistus ja niiden terapeuttinen käyttö | |
| FI934680A7 (fi) | Aryylimorfoliini, valmistus ja käyttö | |
| EE9800451A (et) | Uued imidasotriasolopürimidiinid, nende valmistamismeetod ja kasutamine ravimainetena | |
| FI930716A7 (fi) | Uusia aryylikarbonyyliaminoalkyylidihydro-oksopyridiinejä, niiden valmistus ja käyttö | |
| EE200000207A (et) | 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, nende valmistamine ja terapeutiline kasutamine | |
| FI970750L (fi) | Indoli-2,3-dioni-3-oksimijohdannaisia, niiden valmistus ja käyttö | |
| FI972965A0 (fi) | Uusia peptidejä, niiden valmistus ja käyttö | |
| EE200000018A (et) | 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine | |
| FI964446L (fi) | Uusia tetrapeptidejä, niiden valmistus ja käyttö | |
| FI971317A7 (fi) | Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö | |
| FI950516L (fi) | Interferoni-alfa/beta-sitojaproteiini, sen valmistus ja käyttö | |
| FI965172A7 (fi) | Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: NOVARTIS AG |
|
| FG | Patent granted |
Ref document number: 119191 Country of ref document: FI |
|
| MM | Patent lapsed |